Xenetic Biosciences Statistics
Total Valuation
XBIO has a market cap or net worth of $7.17 million. The enterprise value is -$705,972.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XBIO has 2.29 million shares outstanding. The number of shares has increased by 10.40% in one year.
| Current Share Class | 2.29M |
| Shares Outstanding | 2.29M |
| Shares Change (YoY) | +10.40% |
| Shares Change (QoQ) | +41.35% |
| Owned by Insiders (%) | 8.17% |
| Owned by Institutions (%) | 2.58% |
| Float | 1.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.41 |
| Forward PS | n/a |
| PB Ratio | 0.97 |
| P/TBV Ratio | 0.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.32, with a Debt / Equity ratio of 0.00.
| Current Ratio | 8.32 |
| Quick Ratio | 8.14 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -40.00% and return on invested capital (ROIC) is -26.42%.
| Return on Equity (ROE) | -40.00% |
| Return on Assets (ROA) | -23.21% |
| Return on Invested Capital (ROIC) | -26.42% |
| Return on Capital Employed (ROCE) | -38.33% |
| Weighted Average Cost of Capital (WACC) | 16.37% |
| Revenue Per Employee | $1.49M |
| Profits Per Employee | -$1.34M |
| Employee Count | 2 |
| Asset Turnover | 0.39 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.11% in the last 52 weeks. The beta is 2.21, so XBIO's price volatility has been higher than the market average.
| Beta (5Y) | 2.21 |
| 52-Week Price Change | +12.11% |
| 50-Day Moving Average | 2.84 |
| 200-Day Moving Average | 2.96 |
| Relative Strength Index (RSI) | 52.31 |
| Average Volume (20 Days) | 16,609 |
Short Selling Information
The latest short interest is 14,880, so 0.65% of the outstanding shares have been sold short.
| Short Interest | 14,880 |
| Short Previous Month | 20,598 |
| Short % of Shares Out | 0.65% |
| Short % of Float | 0.84% |
| Short Ratio (days to cover) | 0.71 |
Income Statement
In the last 12 months, XBIO had revenue of $2.98 million and -$2.68 million in losses. Loss per share was -$1.58.
| Revenue | 2.98M |
| Gross Profit | 2.98M |
| Operating Income | -2.83M |
| Pretax Income | -2.68M |
| Net Income | -2.68M |
| EBITDA | n/a |
| EBIT | -2.83M |
| Loss Per Share | -$1.58 |
Full Income StatementBalance Sheet
The company has $7.88 million in cash and $6,655 in debt, giving a net cash position of $7.88 million or $3.44 per share.
| Cash & Cash Equivalents | 7.88M |
| Total Debt | 6,655 |
| Net Cash | 7.88M |
| Net Cash Per Share | $3.44 |
| Equity (Book Value) | 7.40M |
| Book Value Per Share | 3.23 |
| Working Capital | 7.08M |
Full Balance SheetCash Flow
| Operating Cash Flow | -2.29M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -2.29M |
| FCF Per Share | -$1.00 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -95.23% and -90.07%.
| Gross Margin | 100.00% |
| Operating Margin | -95.23% |
| Pretax Margin | -90.07% |
| Profit Margin | -90.07% |
| EBITDA Margin | n/a |
| EBIT Margin | -95.23% |
| FCF Margin | n/a |